In 2020, not only American Baijian Company reported the "good news" of new drugs for Alzheimer's disease. In China, the treatment GV-97 1 with completely independent intellectual property rights, which was jointly developed by the research team of researcher Geng Meiyu from Shanghai Institute of Pharmacology, China Academy of Sciences, China Ocean University and Shanghai Green Valley Pharmaceutical Co., Ltd., has also made progress.
According to official website information of Green Valley Pharmaceutical, in May, 2020, FDA approved its application for international multi-center phase III clinical trial in the United States. In June 2020, 1 1, 97 1 completed the screening of the first batch of patients in the international phase III clinical trial. It is expected that the clinical trial will end in 2025 and it will be listed in Europe and America. Alzheimer's Harmo's disease (AD), commonly known as "Alzheimer's Harmo's disease", is a serious neurodegenerative disease. Patients usually have symptoms such as memory loss and impaired learning ability, accompanied by emotional adjustment disorder and loss of motor ability. This disease is plaguing countless families around the world.